ERBB2 and breast cancer: In the subgroup of patients who received all appropriate treatments, there were 17,112 patients (N = 10,591 ES-TNBC; N = 6521 HR+/HER2- BC) with ≥ 54 months of follow-up (median = 80 months, IQR = 66.0–96.3 months) and 751 events.